{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=83",
    "query": {
      "condition": "Developmental Defect",
      "page": 83
    },
    "page_size": 10
  },
  "pagination": {
    "page": 83,
    "page_size": 10,
    "total_count": 10816,
    "total_pages": 1082,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=84&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=82&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T13:09:24.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01735955",
      "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia (CML)",
        "Metastatic Gastrointestinal Stromal Tumors (GIST)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Receptor Tyrosine Kinase (KIT) Mutated Melanoma"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 57,
      "start_date": "2013-03-29",
      "completion_date": "2023-07-07",
      "has_results": true,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 2,
      "location_summary": "Albany, New York • Houston, Texas",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735955"
    },
    {
      "nct_id": "NCT02052908",
      "title": "Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2014-01-27",
      "completion_date": "2021-01-05",
      "has_results": false,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052908"
    },
    {
      "nct_id": "NCT00914108",
      "title": "Severe Intrauterine Growth Retardation: Developmental Newborn Intensive Care Unit (NICU) Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Intrauterine Growth Retardation",
        "Prematurity"
      ],
      "interventions": [
        {
          "name": "Newborn Individualized Developmental Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "36 Weeks",
        "sex": "ALL",
        "summary": "Up to 36 Weeks"
      },
      "enrollment_count": 30,
      "start_date": "1996-10",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914108"
    },
    {
      "nct_id": "NCT00179517",
      "title": "Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seizure Disorder",
        "Hypogonadism",
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "Anastrozole 1mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2001-06",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2019-07-17",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179517"
    },
    {
      "nct_id": "NCT05708989",
      "title": "Caudal vs. Pudendal Block in Peds GU",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypospadias",
        "Penile Torsion",
        "Chordee",
        "Phimosis"
      ],
      "interventions": [
        {
          "name": "Caudal Block",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasound-guided Pudendal Block",
          "type": "PROCEDURE"
        },
        {
          "name": "Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "3 Years",
        "sex": "MALE",
        "summary": "6 Months to 3 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-06",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708989"
    },
    {
      "nct_id": "NCT00932074",
      "title": "A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "KP-413 Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaken Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 58,
      "start_date": "2009-07",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2012-04-06",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 6,
      "location_summary": "Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more",
      "locations": [
        {
          "city": "Clinton Twp.",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "College Station",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00932074"
    },
    {
      "nct_id": "NCT07137338",
      "title": "A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dilated Cardiomyopathy (DCM)"
      ],
      "interventions": [
        {
          "name": "RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Rocket Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2026-04-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Rochester, Minnesota • Charleston, South Carolina",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07137338"
    },
    {
      "nct_id": "NCT01822015",
      "title": "Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-03-15",
      "completion_date": "2019-12-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822015"
    },
    {
      "nct_id": "NCT04641325",
      "title": "Marfan Syndrome Moderate Exercise Pilot",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Marfan Syndrome"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention Group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 23,
      "start_date": "2020-11-09",
      "completion_date": "2022-12-20",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04641325"
    },
    {
      "nct_id": "NCT07332091",
      "title": "Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis"
      ],
      "interventions": [
        {
          "name": "Vamifeport",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2026-01-22",
      "completion_date": "2028-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-31T13:09:24.728Z",
      "location_count": 20,
      "location_summary": "Gilbert, Arizona • San Diego, California • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332091"
    }
  ]
}